InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules FDA Type C Meeting For HARMONIC Trial Amendments
Lantern Pharma (NASDAQ: LTRN) announced it has scheduled a mid-May 2026 Type C meeting with the U.S. Food and Drug Administration to seek feedback on proposed protocol amendments to its Phase 2 HARMONIC(TM) trial evaluating LP-300 in non-small cell lung cancer. The proposed changes include focusing enrollment on EGFR Exon 21 L858R patients, shifting to a single-arm study design and extending treatment cycles, supported by emerging clinical data…